Back to News
Market Impact: 0.35
Epicyt Pharma reports positive results in first-in-human study of BAFA in patients following gastric bypass surgery
Source: PR Newswire
Healthcare & BiotechProduct Launches
Epicyt Pharma announced positive topline results from its Phase 1/2a first-in-human study of BAFA, a therapy targeting impaired intestinal calcium uptake. The announcement represents a favorable early clinical-development milestone, although the provided article excerpt does not disclose efficacy, safety, or statistical data.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.55
More News
- Vertex reports positive IgAN trial data, FDA decision due Nov. 30
- The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.
- J&J prostate cancer drug shows promising tumor responses in early trial
- Scalpers offer Apple iPhone Duo buyers hundreds extra outside Beijing launch
- Apple’s $2,000 iPhone Duo Debuts With Limited Supply
- Oncologists Cheer Melanoma Data